English
IRBM of Pomezia (Rome) is struggling for the coronavirus vaccine. Andrea Miele, part of the team: “A global effort, a challenge to overcome”
A tour inside the Italian company working to defeat Coronavirus: “1000 doses by May for animal testing and then for human testing. We have already defeated Ebola”. Andrea Miele, an Italian researcher of the team, says: “We are working with the highest cooperation. We turn the strong pressure we feel into huge motivation”
An Italian company, based in Pomezia (Rome), is fighting against a pandemic spreading all over the world. IRBM works in the fields of molecular biotechnology and organic chemistry, and it has already defeated Ebola.
Matteo Liguori, Managing Director of IRBM, introduces us into his company, remotely of course: “IRBM is born in 2010 as a spin-off of a multinational company. In its first ten years it has developed competences, experience and companies. […]At the end of 2010 Advent has been founded, as the cGMP-certified Contract Development and Manufacturing Organization of IRBM Group. Nowadays 20 researchers work in this team”.
The long-lasting partnership with the Jenner Institute of Oxford University does strengthen IRBM’s work: “A project started nine years ago that allowed us to turn into a global reference for innovative vaccines, especially if we speak about adenovirus”. The two partners are collaborating also in this case. “Pressure? We’re used to it – the Managing Director keeps saying – we are trying to achieve our goal as quickly as possible”.
Among Advent staff, Andrea Miele, a 34 years old researcher, says: “We are working with full cooperation. […] What is going on in Italy constitutes a strong pressure but a powerful motivation too.”
Article by Vincenzo Di Vaio published on Orticalab – 02/04/2020
Read the original article on Orticalab
